SANTA CLARA, Calif. (AP) -- Drug developer XenoPort said Friday that its treatment for restless leg syndrome, Horizant, will likely be available to U.S. patients in early June.
Last month XenoPort Inc. said that there was a shortage of Horizant, with patients telling them that they were unable to fill prescriptions. A company representative said at the time that British drugmaker GlaxoSmithKline, which is responsible for making the drug, had run out of its supply.
Horizant was launched in 2011. Last year, the Food and Drug Administration also approved Horizant as a treatment for nerve pain that follows shingles, a viral infection related to chicken pox. XenoPort also is developing potential treatments for Parkinson's disease, multiple sclerosis and psoriasis.
XenoPort said that Horizant shipments to its U.S. distributor have begun.
Shares of the Santa Clara, Calif., company gained 26 cents, or 4 percent, to $6.73 in morning trading. The stock has traded between $5 and $12.98 over the past year.
- Health Care Industry
- restless leg syndrome
- Food and Drug Administration